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Small cell lung cancer cell lines secrete predominantly ACTH
precursor peptides not ACTH
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S_ary A panel of 18 well characterised human small cell lung cancer (SCLC) cell lines was assessed for
the production of adrenocorticotrophin (ACTH) and its precursor peptides, pro-opiomelanocortin (POMC)
and pro-ACTH. These precursor peptides were measured directly using a novel two-site immunoradiometric
assay (IRMA) based on monoclonal antibodies, in conjunction with a similar IRMA for ACTH 1-39.
Significant concentrations of AC[H precursors were secreted by 10 of the 18 cell lines (56%). The low levels
of ACTH immunoreactivity detected in seven cell lines could be accounted for by the known cross-reactivity
of precursors in the ACTH IRMA. This suggests there is little, if any, processing of ACTH precursors to
ACTH. Cell pellet extracts contained undetectable or low levels of ACTH precursors and ACTH, indicating
that these peptides are not stored intracellularly. During the growth of the SCLC cells in vitro ACTH
precursors accumulated progressively in the culture medium. Thus the combination of a direct assay for the
ACTH precursors and the panel of SCLC cell lines provides a valuable in vitro model for the expression of
POMC in human tumours.
Small cell lung cancer (SCLC) is a hormonally active
neoplasm associated with the secretion of a wide range of
peptide hormones. Adrenocorticotrophin (ACTH) is a
notable example, giving rise to gross metabolic derangement
with hypercortisolism and hypokalaemic alkalosis in the
ectopic ACTH syndrome. While this is a relatively unusual
clinical manifestation of SCLC, occurring in 2-3% of cases,
studies investigating the potential role of ACTH as a tumour
marker have indicated that 20-30% of patients have elevated
plasma levels of immunoreactive (ir)-ACTH, without overt
clinical signs of glucocorticoid excess (Ratcliffe et al., 1982).
Further, when lung tumours are extracted and assayed for
ACTH, some 20% of SCLC tumours yield significant
amounts of peptide (Yamaguchi et al., 1985). Thus, the
association of ACTH production with SCLC is sufficiently
strong to address the question of a functional role in the
development or progression of this tumour.
ACTH is synthesised as a high molecular weight (HMW)
precursor, pro-opiomelanocortin (POMC, approximate
molecular weight 31 kD), which is cleaved to an intermediate
peptide, pro-ACTH (molecular weight approximately 22kD)
(Figure 1). It has been suggested that these precursor
peptides do not circulate in normal subjects but may
circulate in pathological conditions, and particularly in the
ectopic ACTH syndrome (Hale et al., 1986).
Characterisation of the molecular species has hitherto only
been possible by chromatographic separation followed by
radioimmunoassay (RIA) of the fractions using antisera to
component peptides from the precursor such as ACTH or
gamma-melanocyte stimulating hormone (gamma-MSH). We
have developed a new approach to quantitating ACTH and
the precursor peptides directly in plasma samples. This
involved the production of a range of monoclonal antibodies
(MAbs) to ACTH and the development of a sensitive two-
site immunoradiometric assay (IRMA) for ACTH (White et
al., 1987). Subsequently an IRMA for the two precursor
peptides, POMC and pro-ACTH has been developed based
on MAbs to ACTH and gamma-MSH (Crosby et al., 1988)
(Figure 1).
SCLC cell lines are now widely used for the study of
tumour biology and provide an appropriate in vitro model
since in vivo studies of hormone secretion are limited by the
rapid clinical course of the disease. We have used these two
novel assays to establish the prevalence of secretion of
ACTH and its precursors in a large panel of cell lines which
were established in several different centres. We have
Correspondence: A. White.
a Precursor IRMA
.0 POMC 0.
[ |IACTH |
I Pro-ACTH C
|ACTH|
icli Y
lA12
b ACTH IRMA
LCiH 4YY
1A12 2A3
Figure 1 Binding sites of the MAbs used in the IRMAs for
ACTH-related peptides. In the precursor IRMA (a), the 1251_
MAb-1A12 recognises ACTH 1018 and the solid phase-linked
MAb-ICIl recognises the gamma-MSH sequence. In the ACTH
IRMA (b), the 1251-MAb-1A12 recognises ACTH 10-18 and the
solid phase-linked MAb-2A3 recognises ACTH 25-39.
examined the influence of culture conditions and the
relationship between cell growth and peptide production.
Materals and methods
Small cell lung cancer cell lines
Ten 'COR' cell lines (COR L24, COR L27, COR L31,
COR L32, COR L42, COR L47, COR L51, COR L88,
COR L99 and COR L103) were established and
characterised as previously described (Baillie-Johnson et al.,
1985). Four NCI SCLC cell lines (NCI H82, NCI H128,
NCI H209 and NCI N417) were made available for study
courtesy of Dr F. Cuttitta (Carney et al., 1985). HC12 and
HX149 were kindly donated by Dr G. Duchesne, Ludwig
Institute for Cancer Research, Sutton, UK (Duchesne et al.,
1987). GLC-1 and GLC-I-M13 were a gift from Dr M.
Brouwer, Netherlands Cancer Institute, Amsterdam, the
Netherlands, and Dr L. de Leij, University of Groningen,
the Netherlands (de Leij et al., 1985). All the cell lines were
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derived from patients with pathologically confirmed SCLC
with the exception of COR L32 which was obtained from a
patient with a poorly differentiated squamous carcinoma of
the lung. The cell line, however, exhibited the characteristics
of SCLC (Baillie-Johnson et al., 1985). The majority of the
cell lines grow as floating aggregates of cells in suspension.
Culture media
Cell lines were routinely cultured in a growth medium,
RS(10), consisting of RPMI 1640 (Gibco, Paisley, Scotland)
supplemented with 10% fetal calf serum (FCS, Gibco), 4mM
glutamine (Flow Laboratonres, Irvine, Ayrshire, UK), 1 mM
sodium pyruvate (Flow) and 10mM N-2-hydroxyethyl-
piperazine-N'-2-ethanesulphonic acid (HEPES) buffer
(Flow). Antibiotics were not used. To determine whether
different culture media influenced ACTH secretion, RS(10)
was compared with two hormone supplemented media, in
which the concentration of FCS was reduced to 2.5%.
RHS(2.5) contained HITES supplements (Carney et al.,
1981), i.e. 10-8M hydrocortisone (Sigma Chemical Co.,
Poole, Dorset, UK, H4001), Spgml - bovine insulin
(Sigma, 15500), 10pgml-1 human transferrin
(Sigma. T2252), 10-8M oestradiol (Sigma, E8875) and
3 x 10-8M sodium selenite (Sigma, S1382). RTISS(2.5)
contained transferrin, insulin and selenite but steroid
hormones were omitted.
Cell culture
All incubations were carried out at 37-C in a 5% CO2
atmosphere. Cells were routinely passaged by diluting the
cultures 2-fold. For growth experiments, cells were pipetted
to reduce the size of the aggregates to 5-10 cells and
passaged by diluting in 100% fresh medium to give a seeding
density of approximately 0.5 x 105cellsml -. Before each
experiment, cells were cultured for at least three passages in
the appropriate growth medium. Cultures were judged to be
'confluent' when crowded with cell aggregates causing the
medium to change to an acid pH. This corresponded with an
approximate cell density of 1 x 106cellsml 1,
Cell counts
Single cell suspensions were prepared by trituration and
viable counts obtained using trypan blue exclusion.
However, for many of the cell lines this provides only an
approximate guide, since it is difficult to disaggregate the cell
clumps without a significant effect on their viability.
Estimation of cellular DNA
DNA was assayed according to a fluorometric method (West
et al., 1985). the fluorochrome dye being Hoechst 33258
(Uniscience. London, UK). The standard was salmon testes
DNA type III (Sigma D1626).
Extraction of cell pellets for ACTH
Cell pellets were immediately frozen on dry ice and stored at
-20-C until extraction. The pellets were thawed, weighed
and 1 ml of 0.01 M HCI added. They were sonicated for
2nmmn, centrifuged at 3,000g for 10min at 4-C, and
supernatants were frozen and stored at -70-C before
ACTH assay. These procedures were optimised for
preservation of ACTH by extraction of exogenous ACT-
added to non-secreting cell lines, and by extraction of
endogenous ACTH from rat pituitary cells.
lmmunoradiometric assay for ACTH
The ACTH IRMA was developed and optimised as
previously described (White et al., 1987) and employs two
MAbs: MAb IA12 (specific for ACTH 10-18) was radio-
iodinated and MAb 2A3 (specific for ACVH 25-39) was
coupled to Sephacryl S300 as solid phase. Human ACTH
standards (NIBSC Code 74/555) were prepared at
concentrations between I and 1,110pmoll-' (4.5-
5,000ng -1). The assay sensitivity (2.5 xstandard deviation
(s.d.) at zero ACTH) is 0.8pmolI-1 (3.5ngl-1) and the
within and between batch coefficients of variation (c.v.) are
<10% at 5-1,110pmoll-' (22-5,000ngl-1) and 6-
1,110pmoll1- (27-5,000ngl -1) respectively. The assay
measures ACTH 1-39 and there is no interference from
fragments of ACTH such as x-MSH, ACTH 18-39 and
ACTH 1-24. Using this combination of ACTH MAbs, the
assay retains some cross-reactivity with the ACTH
precursors (POMC <1% and pro-ACTH <10%).
Immunoradiometric assaj for ACTH precursors
The development of the precursor assay is descnrbed in detail
elsewhere (Crosby et al., 1988). MAb IA12 (specific for
ACTH 10-18) was radio-iodinated and MAb ICl (specific
for gamma1 MSH) was coupled to Sephacryl S300 as solid
phase. A partially purified POMC standard was prepared
from growth medium of a cultured human pituitary tumour
by Sephadex G-75 chromatography under acid dissociating
conditions. The POMC fraction was initially assigned an
arbitrary potency of 10,000 precursor units per litre
corresponding to 26nmol 1-1 asdetermined bythe fluorometric
assay for N-terminal tryptophan (Hakanson & Sundler,
1971). Standards were prepared at concentrations of 2.6-
2,600pmol1-1 The assay sensitivity (2.5 x s.d. at zero
POMC) is 2.6pmoll-1 and the within and between assay
c.v.s are <10% between 20-2,600pmoll1 and 37-
2,600pmoll-1 respectively. Using the POMC standard, pro-
ACTH cross-reacts 100% in this assay, thus it fully
quantitates both ACTH precursor peptides but does not
distinguish between them. Other POMC derived peptides e.g.
ACTH, f-lipotrophin and N-proopiocortin do not cross-
react at levels up to 1,000pmol1I
Sephadex G-75 chromatographk
Growth medium (2ml) from the SCLC cells was acidified
with formic acid (1% final concentration). The acidified
medium was chromatographed on a Sephadex G-75
superfine column (1.5 x 90cm; Pharmacia, Uppsala, Sweden)
and eluted with 1% formic acid containing Polypep
(1 mgml-1) (Sigma P5115) (Ratter et al., 1980). Fractions
(4ml) were immediately neutralised with 5M NaOH
(approximately 85pl) and 0.5M sodium phosphate buffer
(400pd) pH 7.5 and flash frozen before assay. The column
was calibrated with glyceraldehyde-3-phosphate
dehydrogenase (36kD) 125I-prolactin (25kD), alpha-
lactalbumin (14.2kD) and 125I-ACTH 1-39 (4.5kD). Gel
chromatography markers for POMC, pro-ACTH and ACTH
1-39 were obtained from the culture medium of human
pituitary adenoma cells (Crosby et al., 1988).
Results
Detection of ACTH and ACTH precursors
Using a two-site IRMA for ACTH based on monoclonal
antibodies (as shown in Figure 1) low levels of ACTH
immunoreactivity (range 1.4-16.7pmolI ) were initially
detected in culture medium from the SCLC cell lines
COR L24, COR L27, COR L31, COR L42 and COR L103.
Markedly higher levels of the precursors of ACTH were
detected in these cells lines (range 62-3,640pmol -1) with
the precursor assay which directly quantitates POMC and
pro-ACTH without detecting ACTH 1-39. Since POMC and
pro-ACTH cross-react in the ACTH IRMA (< I% and
<10% respectively), secretion of these high levels of ACTH
precursors would account for the ACTH immunoreactivity.
To determine the optimal stage of growth to detect ACTH
precursor peptides, levels were measured throughout the
growth of these five SCLC cell lines over a 14-day period as
shown in Figure 2. ACTH precursor levels increased22 M.F. STEWART et al.
Table I Comparison of peptide levels obtained in three different
growth media
ACTH precursors pmolmg-I DNA
Cell line RS(JO) RHS(2-5) RTISS(2.5)
COR L24 365 62 235
COR L27 77 66 43
COR L31 246 31 64
COR L42 213 175 245
COR L103 119 67 34
Mean(±s.d.) 204 (113) 80 (55) 124 (106)
Days in culture
Figwe 2 Secretion of ACTH precursors throughout cell growth
in five SCLC cell lines. Growth medium=RTISS(2.5). The cell
lines are COR L24 (X X), COR L27 (- *), COR L31
(0QO), COR L42 (A A) and COR L103 (A A).
progressively in the medium as the cells proliferated. This
was accompanied by a parallel increase in the peptide levels
measured in the ACTH IRMA (data not shown). In four of
the five cell lines ACTH precursor levels began to decline by
14 days. The increase in precursors reflected accumulation of
peptides in the medium since endogenously secreted ACTH
precursors were relatively stable in culture medium. This was
assessed by separating peptide-containing medium from cells
and re-incubating at 37 C. ACTH precursor concentrations
were 62% and 74% of the initial values in RS1O and
RTISS 2.5 respectively after 72h incubation.
The five COR cell lines were cultured in three growth
media, RS(10), RHS(2.5) and RTISS(2.5) (Table I). Mean
ACTH precursor levels in confluent cultures were
204pmol mg - DNA, 80pmolmg- I DNA and
124pmolmg 1 DNA respectively. Although RHS(2.5)
(containing 1O-8 M hydrocortisone) gave the lowest mean
level of secretion, this did not hold for all individual cell
lines. RTISS(2.5) was chosen for subsequent experiments as
this had the advantage of reduced serum concentrations.
Further studies are in progress to establish whether the
hydrocortisone in RHS(2.5) was having a specific effect on
ACTH precursor production.
Prevalence of ACTH precursor and ACTH secretion
The prevalence of secretion of both ACTH precursors and
ACTH was formally assessed in all the 18 cell lines
(Table II). Cells were seeded at approximately 0.5 x 105
cells ml- 1 and allowed to proliferate to high density
(approximately 1 x 106 cellsmml'-) without medium change
as this was most likely to yield maximal peptide levels
(Figure 2). Ten of the cell lines (56%) secreted ACTH
precursor peptides giving mean levels of 516pmoll-1. Low
levels of ACTH immunoreactivity (mean 5pmoll-1) were
detected in medium from seven (39%) of the cell lines using
the ACTH IRMA. In cell pellet extracts, ACTH precursors
and ACTH were measurable at only low levels from six
(33%) and three (17%) of the cell lines respectively
(Table ID1).
Chromatography of ACTH-related peptides
Sephadex G-75 chromatography of medium from confluent
cultures of COR L103 (Figure 3) showed that the precursor
IRMA detected two significant peaks of immunoreactivity,
corresponding to 31 kD POMC and 22kD pro-ACTH.
Measurement of fractions with the ACTH IRMA confinmed
that no significant ACTH could be detected. The peak in the
region of 31 kD was not recognised with the ACTH assay
Table H Levels of ACTH and precursor peptides in supernatant
medium
ACTH
Precursors ACTH
No. of (pmoll 1) (pmoll-1) Molar
Cell line observations mean(±s.d.) mean(±s.d.) ratio
COR L24 5 426 (172) 2.6 (1.4) 164:1
COR L27 7 596 (290) 3.4 (1.4) 175:1
COR L31 3 1200 (630) 12.4 (1) 97:1
COR L42 7 1017 (980) 5.2 (2.5) 196:1
COR L88 3 135 (60) <0.8 >135:1
COR L99 1 44 <0.8 >44:1
COR L103 27 1405 (770) 9.0 (2.8) 156:1
NCI H128 3 37 (10) 1.5 (0.2) 25:1
GLC-1-M13 3 198 (190) 1.4 (0.4) 141:1
HC12 3 97 (20) <0.8 >97:1
Mean=516 Mean=5.0
AC-TH precursors <2.6pmol 1 - I and ACTH <0.8pmolI were
observed in the following cell lines on at least three occasions:
COR L32, COR L47, COR L51, NCI H82, NCI H209, NCI N417,
GLC-1, HX149. The cell lines were sampled at a peak viable density
of I x 106 cellsml- 1
Table m Levels of ACTH and precursor
extracts
peptides in cell pellet
Precursors ACTH
Cell line (pmolmg- DNA) (pmolmg-DNA)
COR L24 5.40 n.d.
COR L27 3.30 0.06
COR L31 0.40 n.d.
COR L42 4.40 0.018
COR L103 0.10 n.d.
GLC-1-M13 0.40 0.003
n.d., not detected. Cell pellet extracts in the 12 cell lines not listed
were negative for both AC(TH and precursors.
but a minor peak was detected in the 22kD region,
consistent with the known cross-reactivities of POMC and
pro-ACTH in the ACTH IRMA. This chromatographic
profile is representative in that immunoreactivity
corresponding to authentic ACTH 1-39 could not be
identified in other SCLC cells lines studied (data not shown).
Secretion of ACTH by SCLC cell lines in culture has been
reported previously (Ellison et al., 1976; Sorenson et al.,
1981; Luster et al., 1985a). However, charactensation of
ACTH precursors and estimates of their prevalence in cell
lines as well as in plasma and tumour extracts, has been
limited by technical problems. Previously the precursor
forms could only be detected by chromatographic separation
and analysis of fractions by radioimmunoassay. This is a
relatively insensitive technique and quantitation is critically
dependent on how well the antiserum recognises the HMW
forms, which cannot usually be determined because of the
lack of availability of POMC and pro-ACTH standards.
Thus while HMW precursor forms of AC(TH have been
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demonstrated in SCLC, both in vivo (Hale et al., 1986) and
in vitro (Bertagna et al., 1978), the quantitaton is inexact.
Our approach to the measurement of ACTH precursors
and ACTH using two-site immunoradiometric assays based
on monoclonal antibodies offers many advantages over
earlier methodology. Both assays are simple, robust and
suitable for large numbers of samples, requiring no
extraction procedure. Using these novel assays to detect
ACTH and precursors it was noted that peptide levels were
influenced by culture conditions and an attempt was made to
estimate prevalence under optimal conditions. The rise in
ACTH precursor peptides in medium which occurred as the
cells proliferated reflected accumulation of a stable peptide
and the decline in precursor levels observed at 14 days
coincided with increasing cell death as the nutrient medium
became exhausted and possibly with increased release of
proteolytic enzymes.
We have shown that in this panel of SCLC cell lines,
ACTH precursors are secreted but ACTH 1-39 cannot be
detected to any great extent. ACTH precursor peptides were
synthesised and secreted at significant levels by 10 of the 18
cell lines (56%). The low levels of ACTH detected in the
seven SCLC cell lines were measured in the presence of high
levels of ACTH precursors and reflect the cross-reactivity of
precursors in the ACTH IRMA rather than the presence of
ACTH 1-39 itself. Thus the two-site IRMA for the ACTH
precursors provides a more sensitive approach for the
detection of POMC expression in SCLC cell lines and
because it is a direct quantitative method has demonstrated
that the overwhelming majority of the ACTH secreted is in
HMW precursor forms. Classical Sephadex G-75 chromato-
graphy with measurement of fractions in both the ACTH
IRMA and the precursor IRMA confirmed that ACTH
precursors predominated in culture medium and that
COR L103 cells secreted almost equal amounts of both
POMC and pro-ACTH (Figure 3). No significant levels of
ACTH were detected and while the presence of very small
amounts of ACTH 1-39 cannot be ruled out from this data
alone, it is clear that processing of POMC beyond pro-
ACTH occurs to a negligible extent, if at all, in these tumour
cells.
The frequency of expression of POMC together with the
high levels of peptides secreted, invite speculation on the
significance of ACTH-related peptides in SCLC. Although
no definitive functional role has been ascribed either to
POMC or pro-ACTH, it has been suggested that pro-ACTH
may be bioactive and could give rise to the hypokalaemic
alkalosis, characteristic of the ectopic ACTH syndrome
(Hale et al., 1984). There are also limited and contradictory
reports of the ability of ACTH 1-39 to stimulate the in vitro
growth of SCLC cells (Luster et al., 1985b, Bepler et al.,
1987). It is thought that N-terminal peptides derived from
POMC may have a role in stimulating adrenal growth
(Estivariz et al., 1982), but to date there is no convincing
evidence that ACTH-related peptides act as autocrine or
paracrine growth factors in SCLC. It is of note that the
human POMC gene maps to chromosome 2, in close
proximity to the N-myc oncogene (Hozier et al., 1987)
raising the possibility that POMC expression in SCLC might
occur because abnormal deregulation of DNA in malignant
cells produces activation not only of oncogenes but also of
closely linked marker genes.
In summary, we have applied a direct approach to the
quantitation of ACTH precursors and established that these
peptides are secreted at significant levels by 56% of SCLC
cell lines studied. POMC is processed to pro-ACTH but very
little, if any, ACTH 1-39 is synthesised or secreted by these
tumour cells.
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